Prevalence and Incidence of Complications of Type One Diabetes in pUne at a Tertiary Care centRE (PICTURE)

February 19, 2021 updated by: Dr. Chittaranjan S Yajnik, Kem Hospital, Pune, India

A Study to Assess Prevalence and Incidence of Long-term Complications of Type 1 Diabetes in a Tertiary Clinic in Pune.

Due to early diagnosis (<20yrs of age) of Type 1 Diabetes, patients face longer duration of disease and greater glycemic exposure which makes them more vulnerable towards chronic complications. The aim of this study is to investigate the prevalence and incidence of micro and macro-vascular, pulmonary complications and patterns of growth failure in approximately 500 Type 1 Diabetes patients enrolled at Diabetes Unit, King Edward Memorial Hospital Research Centre. Then follow up of 100 participants who are above 15 years of age at baseline will be done after 2 years to document incidence and progression of complications. This will contribute in assessing the public health burden of complications of Type 1 Diabetes.

Factors associated with prevalence of complications will be investigated. This risk factor analysis could aid in further modifying current prevention and treatment recommendations of these complications. Results of this study could modify current clinical practice.

Study Overview

Status

Unknown

Conditions

Detailed Description

BACKGROUND & RATIONALE OF THE STUDY:

Type 1 Diabetes (T1D) is characterized by progressive destruction of insulin secreting pancreatic β-cells. The commonest mechanism involves autoimmunity to components of β-cells. As per International Diabetes Federation report 2013, India houses 67,700 children (<15yrs) with T1D. It also states an approximate figure of 10,900 newly diagnosed T1D children (<15yrs) per year. India accounts for highest number of children with T1D in South East Asian Region. Karnataka Diabetes Registry of T1D patients (1995 to 2008) reported an incidence of 3.8per 100,000 persons in India which is less when compared to Europe and other Western countries. Same study also reported that there is a huge gap between international standard of care and practice in India and that majority of T1D patients don't attain their glycemic targets.

Despite such unfavorable statistics, T1D does not receive adequate attention in terms of clinical and epidemiological research, achieving standards of practice and training of Medical practitioners. Many a times, it is also quoted as "Poor Cousin of Type 2 Diabetes".

A salient feature of T1D is its early onset and diagnosis (<20yrs of age) compared to type 2 diabetes. Consequently patients face longer duration of disease and greater glycemic exposure by the time they reach productive age and suffer chronic complications which are broadly classified into:

  1. Microvascular (retinopathy, neuropathy, and nephropathy) and
  2. Macrovascular [coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral vascular disease (PVD)] .

These complications contribute to poor quality, substantial morbidity and premature mortality during prime years of life and premature death in T1D patients.

Limited studies are available from India on micro and macro-vascular complication of T1D.

Previous studies have detected that atherosclerotic process is accelerated in T1D population and western studies demonstrated a premature thickening of arterial Intima Media Thickness (IMT) within a short disease duration. Schuyler et al in 1976 for the first time suggested pulmonary complications among T1D. Since then limited attention has been given to lung as a target organ of diabetes even when lungs have a large vascular network. Studies have reported peripheral airway dysfunction and restrictive impairment of lung function even in the absence of smoking, allergies and other causes of airflow destruction among T1D patients. Screening for pulmonary complications among patients with T1D is currently not included in routine clinical settings. Growth parameters like standing height, weight are important indicators of a child's overall health and T1D patients are at an increased risk of developing growth failure. This is due to the role of insulin as a main regulator of Growth Hormone/Insulin Growth Factors (GH/IGF) axis and presence of portal insulin insufficiency among T1D patients. A recent study from Pune reported compromised growth in diabetic children when compared to matched controls. Impaired pre-pubertal and pubertal growth in children and adolescents has been reported in many studies. Factors like gender, age at diagnosis, puberty, metabolic control, insulin regime all affect growth. Bonfig et al 2012 observed a negative association between degree of metabolic control and impaired growth.

Risk factors for complications of T1D have been studied in Western population. Most of them report duration of disease, hyperglycemia, hypertension and dyslipidemia as predictors for micro and macro-vascular complications. But surprisingly "the 50-yr Medalist study" found no association of glycemic control with prevalence of micro-vascular complications.

Research Gap:

The public health burden of T1D is increasing in India and cannot be ignored. Studies assessing long-term complications of T1D from India are limited. They have relatively small sample size, are cross-sectional and retrospective in design. Incidence and progression of these complications has not been reported from India.Prevalence and progression of pulmonary complication among T1D patients has not been studied. Growth data in T1D patients is also limited and will benefit from our study.

Aims and Objectives :

Aim: This thesis will investigate prevalence; incidence and progression of micro-vascular, macro-vascular, pulmonary complications and growth failure among T1D patients in a clinic setting (specialty Diabetes Unit).

  1. OBJECTIVE 1 : To determine the prevalence of long-term complications among T1D patients.
  2. OBJECTIVE 2 : To determine the impact of factors like age, socio-economic status, body mass index (BMI), body fat (adiposity), duration of disease and glycemic control on the prevalence of complications.
  3. OBJECTIVE 3 :To document clinical progression of these complications in duration of 2 years.

Study Type

Observational

Enrollment (Actual)

323

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • India
    • Maharashtra
      • Pune, Maharashtra, India, 411014
        • Diabetes Unit, Kem Hospital Research Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study population includes those people who have been clinically diagnosed with Type 1 Diabetes. These participants will be selected from those enrolled at Diabetes Unit, KEMHRC, Pune, India.

Description

Inclusion Criteria:

  • Type 1 Diabetes with a duration of diabetes more than 1 year.
  • Willingness to participate in the study and sign the consent form.
  • Age : all age groups
  • Gender : Both

Exclusion Criteria:

  • Other forms of diabetes like Type 2 Diabetes, Gestational Diabetes, Fibro Calculus Pancreatic Disease (FCPD), Mature Onset of Diabetes in Young (MODY) etc.
  • People with acute stages of diseases like pneumonia after being treated for the condition.
  • Advanced end stage conditions like Cancer etc.
  • Pregnant and lactating women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of Micro-vascular Complications.
Time Frame: Assessed in one day, approximately.

Following tests will be performed for micro-vascular complications :

  1. RETINOPATHY: Retina scan images
  2. NEPHROPATHY:Urine Albumin : Creatinine ratio), Serum Creatinine, estimated glomerular filtration rate (eGFR)
  3. NEUROPATHY : Michigan Neuropathy Screening Instrument (MNSI) and Biothesiometer.
  4. Pulmonary : Spirometry

Prevalence will be reported as percentage i.e. number of cases divided by total number of study participants , multiplied by 100.
Assessed in one day, approximately.
Prevalence of Macro-vascular Complications.
Time Frame: Assessed in one day, approximately.

Following tests will be performed for macro-vascular complications :

  1. Cardio-Vascular Disease :Blood pressure, Biochemical tests: Lipid Profile [Triglycerides, Cholesterol (HDL, LDL, total)] and ECG (Electrocardiogram > 15 years of age)
  2. Peripheral Vascular Disease : Ankle Brachial Index by Periscope

Prevalence will be reported as percentage i.e. number of cases divided by total number of study participants , multiplied by 100.
Assessed in one day, approximately.
Prevalence of Growth Complications.
Time Frame: Assessed in one day, approximately.
Whole body Anthropometry and Pubertal staging by Tanner's method.
Assessed in one day, approximately.
Incidence of Micro-vascular, Macro-Vascular and Pulmonary Complications.
Time Frame: Assessed in one day, approximately.

Same tools as listed for primary objective 1 will be utilised for measuring incidence of these complications.

- Incidence will be reported as number of new cases per year.
Assessed in one day, approximately.
Progression of Micro-vascular, Macro-Vascular and Pulmonary Complications.
Time Frame: Assessed in one day, approximately.

Same tools as listed for primary objective 1 will be utilised for measuring incidence of these complications.

- Incidence will be reported as number of new cases per year.
Assessed in one day, approximately.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Association of Risk factors with prevalence of complications.
Time Frame: All this data will be collected at the time of primary objective 1 i.e. in one day.

Risk factors are : BMI, Body fat, duration of disease, glycemic control (HbA1C), clinical history, family history, socio-economic status, Lifestyle related: Diet, Physical Activity and substance abuse, Body Composition : whole body Anthropometry and Dual Energy X-ray absorptiometry (DXA).

Risk factors will be used for multivariate analysis with the incidence and prevalence rates, also to report relative risks.
All this data will be collected at the time of primary objective 1 i.e. in one day.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kem Hospital, Pune, India

Investigators

  • Principal Investigator: Chittaranjan Yajnik, MD, FRCP, KEMHRC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 10, 2016

Primary Completion (ACTUAL)

August 31, 2019

Study Completion (ANTICIPATED)

June 30, 2021

Study Registration Dates

First Submitted

February 16, 2017

First Submitted That Met QC Criteria

February 27, 2017

First Posted (ACTUAL)

March 3, 2017

Study Record Updates

Last Update Posted (ACTUAL)

February 23, 2021

Last Update Submitted That Met QC Criteria

February 19, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PhD 19

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 1 Diabetes Mellitus

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe